#ASH17: Syros eviscerated by investor backlash as lead drug flails badly in PhII
It didn’t take long Monday morning to see who the worst performer for the ASH weekend would be. Syros $SYRS cratered quickly once investors got a chance to respond to the hard evidence that their lead drug is failing badly in a Phase II study.
It’s hard to tell from the release, which focused a lot of energy on evidence of clinical activity, but the primary endpoints in the study had to do with overall response rates for acute myeloid leukemia as well as transfusion independence in myelodysplastic syndrome.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.